You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed, Refractory

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Chevy Chase, Maryland
  • +10 more
Jan 12, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

Relapsed/Refractory Multiple Myeloma Trial in United States (Belantamab mafodotin)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Belantamab mafodotin
  • Clayton, North Carolina
  • +4 more
May 16, 2023

Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)

Not yet recruiting
  • Solid Tumor
  • HLA-G-CAR.BiTE allogeneic γδ T cells
  • Taichung, Non-US, Taiwan
    China Medical University Hospital
Nov 27, 2023

Multiple Myeloma Trial (AZD0305)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 24, 2023

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

Not yet recruiting
  • Follicular Lymphoma
  • Axicabtagene Ciloleucel
  • +5 more
  • (no location specified)
Sep 21, 2023

Relapsed/Refractory Acute Leukemia Trial (SNDX-5613)

Available
  • Relapsed/Refractory Acute Leukemia
  • (no location specified)
Jun 15, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Follicular Lymphoma, Refractory Follicular Lymphoma Trial (Tazverik (Tazemetostat))

Not yet recruiting
  • Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Tazverik (Tazemetostat)
  • (no location specified)
Oct 6, 2023

Relapsed/Refractory Multiple Myeloma Trial in Beijing, Hangzhou, Shanghai (LCAR-BCDR cells product)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LCAR-BCDR cells product
  • Beijing, Beijing, China
  • +3 more
Dec 15, 2022

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

Not yet recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

Not yet recruiting
  • B7-H3-positive Relapsed/ Refractory Neuroblastoma
  • T cell injection targeting FLT3 chimeric antigen receptor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Nov 1, 2022

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Jan 19, 2023

Relapsed/Refractory Multiple Myeloma Trial in China (LBL-034 for Injection)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LBL-034 for Injection
  • Wuhu, Anhui, China
  • +6 more
Sep 24, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial (LILRB4 STAR-T cells)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • LILRB4 STAR-T cells
  • (no location specified)
Sep 16, 2022

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023